Insulin therapy is the cornerstone of treatment for type 1 diabetes and the intensification step when type 2 diabetes is not controlled by lifestyle and non-insulin medications. It is also used during pregnancy, in hospitalized patients with hyperglycemia, and short term during severe illness. Modern insulin therapy is built on a hundred years of refinement — from the original animal extracts of 1921 to today’s pen-delivered analogs, smart pens with dose memory, and automated insulin delivery pumps paired with continuous glucose monitors. This guide covers indications, regimens, tools, side effects, and how to start safely.
Why Insulin Is Used
- Type 1 diabetes — autoimmune destruction of pancreatic beta cells eliminates internal insulin production; injected insulin is life-sustaining
- Type 2 diabetes — progressive beta-cell decline often leads to insulin requirement after years of oral and injectable non-insulin therapy
- Gestational diabetes — when diet and metformin or other oral options cannot reach pregnancy glucose targets
- Pregnancy with preexisting diabetes — most oral agents are not used during pregnancy
- Hospitalized hyperglycemia — basal-bolus or IV insulin for inpatient management
- Severe illness or steroid courses — short-term insulin needed even in people otherwise not on insulin
- Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) — IV insulin during the acute phase
When to Start in Type 2 Diabetes
ADA Standards of Care recommend starting insulin in type 2 diabetes when:
- A1C remains above target on maximum tolerated non-insulin therapy
- A1C is above 9 percent with hyperglycemic symptoms at diagnosis
- A1C is above 10 percent regardless of symptoms (insulin first, then taper later if possible)
- Random glucose >300 mg/dL with symptoms
- Catabolic features — unintentional weight loss, ketosis, polyuria — suggesting severe insulin deficiency
Insulin is most often added at this point as a single bedtime basal injection, with the option to expand to basal-plus or basal-bolus if A1C remains above target after several months. See A1C levels for target context.
Regimen Options for Type 2 Diabetes
| Regimen | Daily Injections | Typical A1C Drop | Best Fit |
|---|---|---|---|
| Basal alone (long-acting bedtime) | 1 | 1.5–2.0% | A1C 7.5–9% on oral therapy |
| Basal-plus (basal + 1 prandial) | 2 | 1.7–2.2% | Largest meal drives postprandial spike |
| Basal-bolus | 4+ | 1.8–2.5% | Need flexibility; A1C still high on basal-plus |
| Premix twice daily | 2 | 1.5–2.0% | Consistent meal pattern; simplicity |
| Pump (basal-bolus continuous) | 0 injections; one cannula every 2–3 days | 2.0–3.0% with HCL | Type 1 mainly; selected T2D |
For details, compare basal-bolus insulin regimen and insulin types comparison. For pump-based therapy, see how does an insulin pump work and hybrid closed-loop systems.
Combining Insulin With Other Medications
- Metformin — almost always continued; reduces insulin dose requirement and limits weight gain
- GLP-1 receptor agonists — semaglutide, tirzepatide (technically GLP-1/GIP), liraglutide, dulaglutide; additive A1C reduction, weight loss, cardiovascular and renal benefit; often allow lower insulin doses
- SGLT2 inhibitors — empagliflozin, dapagliflozin, ertugliflozin; cardiovascular and renal benefit; modestly reduce insulin needs; monitor for euglycemic DKA in T1D off-label use
- Sulfonylureas — usually stopped when basal-bolus is started (hypoglycemia overlap); may continue at low dose with basal alone
- DPP-4 inhibitors — typically continued; minor incremental benefit
- Thiazolidinediones — caution for weight gain and fluid retention when combined with insulin
Tools and Devices
- Insulin pens — disposable or reusable; preferred over syringes for convenience and accuracy. See insulin injection pens and reusable insulin pens.
- Pen needles — 4 mm or 5 mm 32G is standard for adults; rotate sites; never reuse
- Smart pens — Inpen and NovoPen Echo Plus log doses, calculate boluses, share data with apps and CGM
- Insulin syringes — still used for U-500 and some pediatric dosing; 0.3 mL syringes for sub-30-unit doses
- Insulin vials — used with syringes or pens; cheaper than pen-only formats
- Pumps — Tandem t:slim X2, Omnipod 5, Medtronic 780G, Tandem Mobi; pair with CGM for hybrid closed loop
- Continuous glucose monitors — Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Guardian; subcutaneous sensors transmit interstitial glucose every 1 to 5 minutes
- Sharps disposal containers — FDA-cleared red containers for used needles; never household trash
Side Effects
| Effect | Frequency | Mitigation |
|---|---|---|
| Hypoglycemia | Common, varies by regimen | CGM; Rule of 15; carry glucagon; structured education |
| Weight gain (2–4 kg yr 1) | Common | Pair with metformin or GLP-1 RA; carb-aware eating |
| Injection site reactions | 3–5% | Rotate sites; warm pen; fresh needle each time |
| Lipohypertrophy | 30–50% with poor rotation | Strict rotation plan; check sites every 3 months |
| Hypokalemia | Inpatient mainly | Monitor and replete potassium |
| Allergic reactions | Rare | Switch formulation; allergist if anaphylaxis |
| Edema | Uncommon | Avoid TZD combination if relevant |
| Insulin antibodies, lipoatrophy | Very rare with modern analogs | Switch insulin type |
Barriers and “Psychological Insulin Resistance”
- Fear of needles — most resolves with pen devices and 4 mm 32G needles
- Sense of personal failure (“did not try hard enough”) — frame as disease progression, not patient failure
- Fear of hypoglycemia — CGM, structured initiation, hypo response training
- Lifestyle disruption — pen devices fit in pocket; pumps reduce injection count
- Stigma about insulin use — peer support, online communities
- Cost concerns — 35 dollar/month caps; assistance programs; OTC human insulin if needed
- Storage and travel complications — see insulin storage and best insulin travel case cooler
Initiation Workflow
- Confirm indication and discuss expectations with patient and family.
- Select regimen — typically basal alone in insulin-naive T2D.
- Select insulin product — usually glargine, detemir, or degludec; consider cost, dosing flexibility, hypoglycemia history.
- Calculate starting dose — 10 units bedtime or 0.1 to 0.2 u/kg.
- Train patient on pen use, injection technique, site rotation, storage, and hypoglycemia response.
- Provide written sick-day plan and emergency contact information.
- Schedule follow-up in 1 to 2 weeks for early titration.
- Apply the ADA “2-by-3” titration protocol — see insulin dosing guidelines.
- Consider CGM at start to make titration safer.
- Re-evaluate at 3 months — if A1C still above target, intensify to basal-plus, basal-bolus, or premix.
Evidence Base — Insulin in Type 2 Diabetes
The UK Prospective Diabetes Study (UKPDS 33) randomized newly diagnosed type 2 diabetes patients to conventional therapy or intensive therapy with insulin or sulfonylurea. The intensive arm achieved an A1C of 7.0 percent versus 7.9 percent and showed 12 percent reduction in any diabetes-related endpoint and 25 percent reduction in microvascular complications. The DCCT had earlier demonstrated equally strong benefits of intensive insulin therapy in type 1 diabetes. Together these trials established A1C reduction and intensive insulin management as standards of care.
Lifestyle Integration
- Meal timing — rapid analogs ideally 0 to 15 minutes before eating; ultra-rapid forms can be given at meal start
- Activity — see dosing guidelines for exercise adjustments
- Travel — keep insulin in carry-on luggage; pack twice the supplies needed; use a cooling pouch in hot climates
- Work shifts — coordinate basal timing with sleep-wake schedule; degludec is most forgiving of shift changes
- Driving — check BG before driving; carry fast carbs; ADA Driving Recommendations apply
- Alcohol — can cause delayed hypoglycemia; pair with food; reduce evening basal if heavy drinking
Long-Term Outlook
Modern analog insulin therapy combined with CGM and hybrid closed-loop pumps achieves the lowest A1C and highest time-in-range in diabetes history while reducing hypoglycemia. People with type 2 diabetes who start insulin can sometimes transition off it after glucose toxicity reverses and beta-cell function partially recovers. People with type 1 diabetes will require insulin lifelong but increasingly with automated systems that reduce day-to-day burden. See also is prediabetes reversible for context on earlier disease stages.
External Sources
For the long-term outcomes of intensive insulin therapy in type 2 diabetes, see the UKPDS 33 trial published in The Lancet 1998. For comprehensive contemporary guidance, see the ADA Standards of Care in Diabetes 2024.
The Bottom Line
Insulin therapy is required in type 1 diabetes and added in type 2 diabetes when A1C remains above target or at diagnosis with severe hyperglycemia. Starting regimens include basal alone, basal-plus, full basal-bolus, twice-daily premix, or pump. Modern analogs, smart pens, and CGM make insulin safer and easier than ever. Side effects center on hypoglycemia, weight gain, and injection acceptance, all manageable with structured initiation and education. Cost concerns have been largely addressed by 35 dollar/month caps and OTC human insulin options. Work with your clinician to choose a regimen that fits your physiology and your life.
